磷酸西格列汀治疗2型糖尿病56例临床观察
2017-05-17张亚娜
张亚娜

[摘要] 目的 观察对2型糖尿病予以磷酸西格列汀治疗的临床效果。方法 选取该院在2013年7月—2016年7月间所收治的2型糖尿病患者56例作为临床对象,随机分成对照组、观察组。对照组予以降糖药口服治疗,观察组予以磷酸西格列汀治疗,观察与比较两组临床疗效。结果 观察组的血糖得以控制状况明显优于其对照组,HbA1c指标降低状况好于对照组,差异有统计学意义(P<0.05)。 结论 对2型糖尿病患者予以磷酸西格列汀治疗,获取了显著的临床效果,将HbA1c指标显著降低,可以在临床上进行广泛的推广。
[关键词] 磷酸西格列汀;2型糖尿病;临床效果
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)01(b)-0070-02
[Abstract] Objective To observe the clinical effect of sitagliptin phosphate in treatment of 56 cases with type 2 diabetes. Methods 56 cases of patients with type 2 diabetes admitted and treated in our hospital from July 2013 to July 2016 were selected and randomly divided into two groups, the control group took the hypoglycemic orally, while the observation group were treated with sitagliptin phosphate, and the clinical curative effect was observe and compared. Results The blood sugar control situation in the observation group was obviously better than that in the control group, the decrease of HbA1c index was better than that in the control group, and the statistical analysis showed that there was an obvious difference(P<0.05). Conclusion The sitagliptin phosphate treatment for patients with type 2 diabetes can obtain an obvious clinical effect and obviously decrease the HbA1c index, which can be widely promoted in clinic.
[Key words] Sitagliptin phosphate; Type 2 diabetes; Clinical effect
糖尿病是临床上具有慢性进展特征的一种疾病,且每年的病发人数在逐渐增多,其中患有2型糖尿病约占93%左右,多数临床患者在常规治疗中主要是对血糖控制,但是,即便是运用很多药物进行控制性治疗,依旧在国内超过半数以上的临床患者对血糖实施控制不能达至理想效果。常规治疗在临床应用中存在很多缺点,如:将体重增加,会产生低血糖的风险,有胃肠的不良反应产生,或是水肿以及不能对餐后的血糖进行有效控制。在临床的实际应用之中存有较大的局限,但是,磷酸西格列汀能够对胰腺β细胞的合成进行促进,对胰岛素进行释放,且将胰腺α细胞所分泌出的胰高血糖素减少,因此,能够较好改善血糖指标,不会将患者的体重增加[1]。该文选取该院56例临床患者予以回顾性分析,现报道如下。
1 资料与方法
1.1 一般资料
选取该院在2013年7月—2016年7月间所收治的2型糖尿病患者56例作为临床资料,随机分成对照组、观察组,每组28例。……
